Bates, Susan E.

Multidrug resistance in cancer: role of ATP–dependent transporters

Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer

Drug Transport and Resistance MechanismsAntibiotic Resistance in Bacteria

Cited by 5,536

Tumour stem cells and drug resistance

Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer

Cancer Cells and MetastasisDrug Transport and Resistance Mechanisms

Cited by 3,668

Revisiting the role of ABC transporters in multidrug-resistant cancer

Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer

Drug Transport and Resistance MechanismsAntibiotic Resistance in Bacteria

Cited by 1,866

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Kelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., Yau, T., Klümpen, H.-J., Chan, S. L., Ozaka, M., et al. (2023) · The Lancet

Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments

Cited by 1,169

Randomized Phase III trial of Pegvorhyaluronidase Alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma

Van Cutsem, E., Tempero, M. A., Sigal, D., Oh, D.-Y., Fazio, N., Macarulla, T., Hitre, E., Hammel, P., Hendifar, A. E., Bates, S. E., et al. (2020) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 499

Clinical Toxicities of Histone Deacetylase Inhibitors

Subramanian, S., Bates, S. E., Wright, J. J., Espinoza-Delgado, I., & Piekarz, R. L. (2010) · Pharmaceuticals

Histone Deacetylase Inhibitors ResearchEpigenetics and DNA Methylation

Cited by 386

ABCG2-mediated transport of photosensitizers: Potential impact on photodynamic therapy

Robey, R. W., Steadman, K., Polgar, O., & Bates, S. E. (2005) · Cancer Biology & Therapy

Drug Transport and Resistance MechanismsPhotodynamic Therapy Research Studies

Cited by 204

Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2

To, K. K. W., Robey, R. W., Knutsen, T., Zhan, Z., Ried, T., & Bates, S. E. (2009) · Molecular Cancer Therapeutics

Drug Transport and Resistance MechanismsMicroRNA in disease regulation

Cited by 112

Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 ( SLFN11) Expression with Class I Histone Deacetylase Inhibitors

Tang, S.-W., Thomas, A., Murai, J., Trepel, J. B., Bates, S. E., Rajapakse, V. N., & Pommier, Y. (2018) · Clinical Cancer Research

Histone Deacetylase Inhibitors ResearchEpigenetics and DNA Methylation

Cited by 94

Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure

Robey, R. W., Shukla, S., Steadman, K., Obrzut, T., Finley, E. M., Ambudkar, S. V., & Bates, S. E. (2007) · Molecular Cancer Therapeutics

Drug Transport and Resistance MechanismsPharmacogenetics and Drug Metabolism

Cited by 61

Targeting Translation of mRNA as a Therapeutic Strategy in Cancer

Pal, I., Safari, M., Jovanovic, M., Bates, S. E., & Deng, C. (2019) · Current Hematologic Malignancy Reports

RNA and protein synthesis mechanismsPI3K/AKT/mTOR signaling in cancer

Cited by 46